12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

MoxDuo IR morphine/oxycodone regulatory update

QRxPharma said it received a complete response letter from FDA for an NDA for MoxDuo IR morphine/oxycodone to treat moderate to severe acute pain. The company said the agency requested clarity on the product's safety and effectiveness, but did not request additional trials. On a conference...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >